- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05170451
Topical CBD for Musculoskeletal Pain
A Randomized Controlled Trial of Topical Cannabidiol for the Treatment of Musculoskeletal Pain
Rationale: CBD is commonly being used as an over-the-counter treatment for musculoskeletal pain; however, no clinical trial has been performed to establish efficacy of CBD in humans for musculoskeletal pain.
Hypothesis: CBD is more effective than placebo for relieving pain and improving patient-reported outcomes for musculoskeletal pain.
Study Design: The study design with be a double-blind, randomized controlled trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the CBD or control and then crossover to the other condition for 2 additional weeks. Patients will apply the CBD or control cream to the affected area twice daily (approximately every 12 hours) for 1 hour. Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
Study Overview
Detailed Description
Study Population: 100 subjects presenting with musculoskeletal pain over the age of 18 will be recruited from the University of Virginia from the Hand Center or Primary Care Clinic.
Description of Sites/Facilities Enrolling Participants: This will be a single-site study conducted at the University of Virginia in the Hand Center and the Primary Care Clinic.
Description of Study Intervention: The study design will be a double-blind randomized control trial with crossover. Treatment will be blinded to the subjects and investigators. Patients will be randomly assigned 2 weeks of the case (CBD) or control cream and then crossover to the other cream for 2 more weeks with a 1-week washout interval between. Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour. The subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects. If mild to severe adverse events are noticed, the creams will be removed immediately, and appropriate care and observation will be taken. Each condition will last for 2 weeks and then subjects will be contacted by the study coordinator to facilitate crossover into the other condition following a 1-week washout period. To capture any delayed-onset adverse events, including those related to skin changes that might develop after the drug is discontinued, subjects will attend a follow-up visit seven days following the last dose of investigational cream.
Study Duration: This study will last one year from the beginning of subject recruitment to data analysis.
Participant Duration: Subjects will be enrolled in this study for approximately seven (7) weeks from Screening until the final Study Visit.
Study Type
Phase
- Phase 2
- Phase 3
Contacts and Locations
Study Locations
-
-
Virginia
-
Charlottesville, Virginia, United States, 22903
- University of Virginia
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- Provision of signed and dated informed consent form.
- Stated willingness to comply with all study procedures and availability for the duration of the study.
- Male or female, aged 18 years or older.
- Females of childbearing potential must have a negative urine and blood pregnancy test at Screening and a negative urine pregnancy test before study drug is administered. Females must abstain from sex or use a highly effective method of contraception during the period from Screening to administration of study drug and for 30 days after the last dose of study medication. Standard acceptable methods include abstinence or the use of a highly effective method of contraception, including; hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom with spermicide, vasectomy, intrauterine device. If females are of non-child bearing potential, they must be post-menopausal defined as: age > 55 with no menses within the past 12 months, or history of hysterectomy, or history of bilateral oophorectomy, or bilateral tubal ligation.
- Males must consent to use a medically acceptable method of contraception throughout the entire study period and for 90 days after their last study drug application. They must agree to not donate sperm for 90 days after their last study drug application.
- Presence of physician-diagnosed musculoskeletal pain in a discrete body region, including bone or joint-related pain, tendon or ligament-related pain, muscle-related pain, or fibromyalgia or physician-diagnosed postoperative pain in a discrete body region.
Exclusion Criteria:
- Subject does not speak English.
- Subject is blind.
- Severe cardiac, pulmonary, liver and /or renal disease.
- Coumadin use at time of screening.
- History of mental illness.
- Subjects who are incarcerated.
- History of drug or substance abuse.
- Pre-existing CBD or hemp-based product usage.
- Subject has had a corticosteroid injection ≤ 3 months prior.
- Subject has had prior surgery for osteoarthritis treatment.
- Females who are pregnant, nursing or planning a pregnancy; females of childbearing potential who are unwilling or unable to use an acceptable method of contraception as outlined in this protocol from Screening to the first dose of study medication and for 30 days after the last dose of study medication. Standard acceptable methods include abstinence or the use of a highly effective method of contraception, including; hormonal contraception, diaphragm, cervical cap, vaginal sponge, condom with spermicide, vasectomy, intrauterine device.
- Any skin disease or condition, including eczema, psoriasis, melanoma, acne or contact dermatitis, scarring, imperfections, lesions, tattoos or discoloration that may affect treatment application, application site assessments, or affect absorption of the study drug.
- Subjects with ALT/AST >3 times the upper limit of normal at screening.
- Subjects with history of or active depression or suicide ideation based on Columbia-Suicide Severity Rating Scale (C-SSRS).
- Subjects taking prescription or non-prescription medication which are substrates of CYP3A4 (Itraconazole, Ketoconazole, Azamulin, Troleandomycin, Verapamil, John's wart, Phenobarbital), CYP2C19 (Nootkatone, Ticlopidine, Rifampin, Omeprazole), CYP2C8 (Montelukast, Quercetin, Phenelzine, Rifampin, Clopidogrel) , CYP2C9 (Sulfaphenazole, Tienilic acid, Carbamazepine, Apalutamide, Fluconazole, Celecoxib), CYP1A2 (alpha-Naphthoflavone, Furafylline, Phenytoin, Rifampin, Ritonavir, smoking, Teriflunomide, Ciproflaoxacin, oral contraceptives, Alloprinol) and CYP2B6 (Sertraline, Phencyclidine, Thiotepa, Ticlopidine, Carbamazepine, Efavirenez, Rifampin, Bupropion) within 14 days of the study procedure.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Quadruple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Active Comparator: Active Comparator: Start with CBD
The study design with be a double-blind, randomized controlled trial with crossover.
Treatment will be blinded to the subjects and investigators.
Patients will be randomly assigned 2 weeks of the CBD and then crossover to the other condition (Shea butter only) for 2 additional weeks.
Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour.
Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
|
Topical CBD 50 mg/ml applied in 1mL amounts twice daily
Topical shea butter applied in 1mL amounts twice daily
Other Names:
|
Active Comparator: Active Comparator: Start with control (Shea butter)
The study design with be a double-blind, randomized controlled trial with crossover.
Treatment will be blinded to the subjects and investigators.
Patients will be randomly assigned 2 weeks of Shea butter and then crossover to the other condition (CBD) for 2 additional weeks.
Patients will apply the topical cream to the affected body region or joint two times daily for 1 hour.
Subjects will be advised to observe for physiologic changes, skin changes, or other adverse effects.
|
Topical CBD 50 mg/ml applied in 1mL amounts twice daily
Topical shea butter applied in 1mL amounts twice daily
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Number of participants with change in The PROMIS-29 (Patient-Reported Outcomes Measurement Information System) during intervention and at follow-up.
Time Frame: [Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
PROMIS-29 will measure health-related quality of life and is a validated, 29 question survey divided into seven sub-domains of function including physical functioning, social function, pain interference, pain intensity, sleep, depression, and anxiety, where a higher score indicates more pain interference.
|
[Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
Change from baseline in Single Assessment Numerical Evaluation (SANE)
Time Frame: [Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
The SANE score is a validated metric for musculoskeletal pain which can be applied to any joint or region of interest.
The patient is asked to rate his/her pain from 0-100.
Patients rate their current illness score in relation to their pre-injury baseline.
|
[Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
Change from baseline in Visual Analog Pain (VAS) Score during intervention and at follow-up.
Time Frame: [Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
The VAS score is a unidimensional measure of pain intensity and is a validated, subjective measure for acute and chronic pain.
A patient is asked to indicate his/her perceived pain intensity along a horizontal line (from 0 to 100), and this rating is then measured from the left edge with higher numbers indicating more pain.
|
[Time Frame: Every 1 week during intervention and 1 week washout, up to 7 weeks.]
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Rate of side effects using novel CBD cream.
Time Frame: [Time Frame: Daily during intervention and 1 week washout, up to 7 weeks.]
|
Side effects will be assessed at each encounter clinical evaluation by patient report in a Symptom Diary.
All side effects thought to be secondary to CBD will be documented.
|
[Time Frame: Daily during intervention and 1 week washout, up to 7 weeks.]
|
Collaborators and Investigators
Sponsor
Investigators
- Principal Investigator: Brent DeGeorge, MD, PhD, University of Virginia
Study record dates
Study Major Dates
Study Start (Estimated)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- HSR200170
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Musculoskeletal Pain
-
Sykehuset i Vestfold HFActive, not recruitingBack Pain | Musculoskeletal Pain | Chronic Pain | Musculoskeletal Diseases or Conditions | Pain, Chronic | Musculoskeletal Disorder | Musculoskeletal Neck PainNorway
-
University of Missouri, Kansas CityTerminatedOrthopaedic Related Pain (Musculoskeletal Pain)United States
-
Uppsala UniversityDalarna County Council, Sweden; Center for Clinical Research Dalarna, Sweden; REHSAM, SwedenTerminatedMusculoskeletal Neck Pain | Musculoskeletal Shoulder PainSweden
-
NORCE Norwegian Research Centre ASHelse Sor-Ost; Sykehuset i Vestfold HFCompletedNeck Pain Musculoskeletal | Back Pain Lower BackNorway
-
Stanford UniversityNational Institute of Neurological Disorders and Stroke (NINDS)RecruitingPain | Joint Pain | Pain, Chronic | Chronic Musculoskeletal PainUnited States
-
University of North Carolina, Chapel HillYale University; Duke University; National Institute on Aging (NIA); Indiana University and other collaboratorsCompletedChronic Pain | Acute Musculoskeletal PainUnited States
-
Massachusetts General HospitalOrthopaedic Trauma AssociationCompleted
-
Wayne State UniversityUniversity of MichiganCompleted
-
Wayne State UniversityBlue Cross Blue Shield of Michigan FoundationCompleted
-
Wayne State UniversityUniversity of Southern CaliforniaCompleted
Clinical Trials on CBD
-
Hartford HospitalYale UniversityActive, not recruiting
-
Johns Hopkins UniversityCultivate BiologicsCompleted
-
University of Texas at AustinWay West Wellness; SunFlora.IncSuspendedAnger | Sleep Disturbance | Anxiety Depression | Substance Abuse | Alcohol Abuse | Stress ReactionUnited States
-
Universidad de GranadaActive, not recruiting
-
Advanced Pain and Rehab SpecialistsHemp synergisticsNot yet recruitingInsomnia | Anxiety | Opioid Use | Pain, Chronic | CBDUnited States
-
University of Texas at AustinSuspendedPost Traumatic Stress DisorderUnited States
-
Pure GreenRecruitingOsteoarthritis, KneeUnited States
-
University of CalgaryNot yet recruitingChronic Migraine
-
Wake Forest University Health SciencesNational Institute on Drug Abuse (NIDA); University of North Carolina, Chapel... and other collaboratorsCompleted
-
Canopy Growth CorporationNM Clinical Research & Osteoporosis Center, Inc.Terminated